Published in Cancer Weekly, June 12th, 2006
CA4P is being evaluated in a phase 2 clinical trial in combination with the widely used chemotherapy regimen, carboplatin and paclitaxel, for the treatment of platinum resistant ovarian cancer. Results previously reported from a phase 1b clinical trial showed a 67% response rate to the combined...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.